Medical treatment of unresectable hepatocellular carcinoma: Going beyond sorafenib

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 3

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

284

HTML

2582

Figures (1-2)

279

Tables (1-3)

260

Sum=3405

Mar 27, 2010 (publication date) through Feb 21, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Guidelines For Clinical Practice

World J Hepatol. Mar 27, 2010; 2(3): 103-113
Published online Mar 27, 2010. doi: 10.4254/wjh.v2.i3.103

Table 3 Summary of the results obtained so far with Bevacizumab and Bevacizumab-based combinations in HCC

	Development	Comments
Bevacizumab	As single agent, i.v. route	Active (high DCR), but increased risk of bleeding from esophageal varices
	As single agent, i.v. route
	As single agent, i.a. route	Promising early results
	In combination with other molecularly targeted agents, e.g. erlotininib	Active (high ORR), but toxic
	In combination with chemotherapy	Not particularly active and toxic

Citation: Porta C, Paglino C. Medical treatment of unresectable hepatocellular carcinoma: Going beyond sorafenib. World J Hepatol 2010; 2(3): 103-113
URL: https://www.wjgnet.com/1948-5182/full/v2/i3/103.htm
DOI: https://dx.doi.org/10.4254/wjh.v2.i3.103